Chromogenic anti-FXa assay calibrated with low molecular weight heparin in patients treated with rivaroxaban and apixaban: possibilities and limitations

INTRODUCTION: Clinical application of rivaroxaban and apixaban does not require therapeutic monitoring. Commercial anti-activated factor X (anti-FXa) inhibition methods for all anti-FXa drugs are based on the same principle, so there are attempts to evaluate potential clinical application of heparin...

Descripción completa

Detalles Bibliográficos
Autores principales: Margetić, Sandra, Ćelap, Ivana, Delić Brkljačić, Diana, Pavlović, Nikola, Šupraha Goreta, Sandra, Kobasić, Ivana, Lovrenčić-Huzjan, Arijana, Bašić Kes, Vanja
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Croatian Society of Medical Biochemistry and Laboratory Medicine 2019
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6904970/
https://www.ncbi.nlm.nih.gov/pubmed/31839722
http://dx.doi.org/10.11613/BM.2020.010702

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6904970/
https://www.ncbi.nlm.nih.gov/pubmed/31839722
http://dx.doi.org/10.11613/BM.2020.010702

Ejemplares similares